Investigating how genetic differences affect heart cell responses to cancer drugs
Single-cell Multi-omic Profiling of Drug Responses Using Pooled iPSC-CM Differentiation
This study is looking at how your unique genes might affect how your heart reacts to doxorubicin, a cancer treatment that can sometimes harm the heart, so that doctors can find better ways to keep patients safe while treating their cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project ID | NIH-11138577 on NIH RePORTER |
What this research studies
This research focuses on understanding how individual genetic variations influence the heart's response to doxorubicin, a common cancer treatment known to cause heart damage. By creating 'cell villages' using induced pluripotent stem cells (iPSCs) from multiple patients, researchers will differentiate these cells into heart cells and analyze their responses to the drug at a single-cell level. This approach aims to identify genetic factors that predict which patients are at risk for heart complications from cancer therapy. The findings could lead to better personalized treatment strategies for cancer patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are cancer patients who are being treated with doxorubicin and may be at risk for heart complications.
Not a fit: Patients who are not undergoing cancer treatment or those who are not receiving doxorubicin are unlikely to benefit from this research.
Why it matters
Potential benefit: If successful, this research could help identify patients at risk for heart damage from cancer treatments, allowing for tailored therapies that minimize adverse effects.
How similar studies have performed: Previous research has shown promise in using genetic profiling to predict drug responses, suggesting that this approach could yield valuable insights.
Where this research is happening
Stanford, United States
- Stanford University — Stanford, United States (Active)
Researchers
- Principal investigator: Wu, Joseph C. — Stanford University
- Study coordinator: Wu, Joseph C.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.